J2KBIO Co., Ltd. (420570) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of J2KBIO Co., Ltd. KRW 10,056, price KRW 9,220, upside +9.1%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch J2KBIO Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
J2KBIO Co., Ltd., a bio venture company, offers active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation. The company was founded in 2014 and is based in Cheongju, South Korea.
Stock analysis
J2KBIO Co., Ltd. (420570) currently trades at 9,220 KRW, while our model-based Fair Value estimate is 10,056 KRW, implying the stock looks roughly 8.3% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 12,350 KRW per share, and 13 of the 24 models we run sit above the 9,220 KRW price.
Bear case: the Asset-Based group reads lowest at 3,870 KRW, and 11 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 6,884 KRW (bear) to 12,570 KRW (bull), the price of 9,220 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Basic Materials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
J2KBIO Co., Ltd. reported revenue of 33.0B KRW in FY2025 versus 14.2B KRW in FY2021, a compound +23.4%/yr. Reported net income was 2.7B KRW in FY2025, compounding +13.3%/yr from FY2021.
Key figures
Market cap 53.9B KRW (≈ $39.6M) · P/S ratio 1.24 · Dividend yield 2.7% · Net margin 8.1% · Return on equity 12.4% · Return on assets (EBIT) 13.6% · Operating margin 17.2% · Revenue (TTM) 36.8B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −40% fair-value upside, at 9%, 420570 screens cheaper than that median.
Fair Value models
Bear 6,884 KRWFair Value 10,056 KRWBull 12,570 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.80/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.2%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.3%
Dividend (yield on the price)2.7%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 9%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +19.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 713 stocks
Beats the industry median on 10/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score53 · Above median
Fair Value upside+9% · Above median
Profitability
Return on equity (TTM)12% · Top 25%
Return on assets7% · Top 25%
Net margin (TTM)11% · Top 25%
Operating margin (TTM)17% · Top 25%
Growth and dividend
Revenue growth53% · Top 25%
Dividend yield (TTM)2.7% · Above median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is J2KBIO Co., Ltd. (420570) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10,056 KRW versus a price of 9,220 KRW, about +9% upside (fairly valued).
What is the fair value of 420570?
Our model-based fair value for J2KBIO Co., Ltd. is 10,056 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 9,220 KRW.
What is the quality score of 420570?
J2KBIO Co., Ltd. has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for J2KBIO Co., Ltd. (420570)?
Our model-based price target is the fair value of 10,056 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 6,884 KRW, optimistic scenario 12,570 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the J2KBIO Co., Ltd. stock forecast for 2026?
Our models put fair value at 10,056 KRW, about +9% upside versus a price of 9,220 KRW (fairly valued). Cautious scenario 6,884 KRW, optimistic scenario 12,570 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of J2KBIO Co., Ltd. (420570)?
J2KBIO Co., Ltd. reported trailing-twelve-month revenue of about 36.8B KRW (latest available figure, as of Sep 24, 2026).
Does J2KBIO Co., Ltd. pay a dividend?
J2KBIO Co., Ltd. currently shows a dividend yield of about 2.71% relative to its recent price (as of Sep 24, 2026).
What growth is priced into J2KBIO Co., Ltd. (420570)?
For today's price to be fair in a discounted-cash-flow model, J2KBIO Co., Ltd. would have to grow free cash flow by +22.0 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +23.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 420570 use?
Our models discount J2KBIO Co., Ltd. at 8.9 %: a base by market capitalisation (nano), damped by beta 0.50, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For J2KBIO Co., Ltd. that is +22.0 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has J2KBIO Co., Ltd. (420570) delivered so far?
Over the past 4 years revenue at J2KBIO Co., Ltd. grew +23.4 % a year. The price currently implies +22.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of J2KBIO Co., Ltd. (420570) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into J2KBIO Co., Ltd. (+22.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of J2KBIO Co., Ltd. (420570)?
The free-cash-flow yield on the price is 1.75 %: that much free cash flow J2KBIO Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of J2KBIO Co., Ltd. (420570)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For J2KBIO Co., Ltd. it is 10,056 KRW per share (as of Sep 24, 2026), against a price of 9,220 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is J2KBIO Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 420570 trades below its calculated fair value: price 9,220 KRW, fair value 10,056 KRW, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 420570?
No. The price is what the market pays today (9,220 KRW); the fair value is what the company's own numbers justify (10,056 KRW). For J2KBIO Co., Ltd. the two are 836.03 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is J2KBIO Co., Ltd. worth?
The market values J2KBIO Co., Ltd. at about 53.9B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 9,220 KRW; our models calculate a fair value of 10,056 KRW per share.
What do the bullish and bearish scenarios say about 420570?
Our models span a range for J2KBIO Co., Ltd.: cautious scenario 6,884 KRW, base 10,056 KRW, optimistic 12,570 KRW per share (as of Sep 24, 2026, price 9,220 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of J2KBIO Co., Ltd. (420570)?
Balance-sheet figures for J2KBIO Co., Ltd. (as of Sep 24, 2026): return on equity 12.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 420570 from its 52-week high?
J2KBIO Co., Ltd. trades at 9,220 KRW, about 23% below its 52-week high of 12,000 KRW and 33% above the low of 6,950 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 10,056 KRW is for.
Which stocks are comparable to J2KBIO Co., Ltd.?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is J2KBIO Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 9,220 KRW, calculated fair value 10,056 KRW (+9%), Quality Score 53/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 420570 calculated?
We run J2KBIO Co., Ltd. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10,056 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. J2KBIO Co., Ltd. currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of J2KBIO Co., Ltd. (420570)?
The closing price on Sep 23, 2026 was 9,220 KRW. Our model-based fair value is 10,056 KRW, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with J2KBIO Co., Ltd. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (6,884 KRW to 12,570 KRW) leaves room in how you read the outcome.
Key figures of J2KBIO Co., Ltd.
How large is the market capitalisation of J2KBIO Co., Ltd. (420570)?
The market capitalisation of J2KBIO Co., Ltd. is 53.9B KRW (≈ $39.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of J2KBIO Co., Ltd. (420570)?
The price-to-sales ratio of J2KBIO Co., Ltd. is 1.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of J2KBIO Co., Ltd. (420570)?
The dividend yield of J2KBIO Co., Ltd. is 2.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of J2KBIO Co., Ltd. (420570)?
The net margin of J2KBIO Co., Ltd. is 8.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of J2KBIO Co., Ltd. (420570)?
The return on equity (ROE) of J2KBIO Co., Ltd. is 12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of J2KBIO Co., Ltd. (420570)?
On an EBIT basis the return on assets of J2KBIO Co., Ltd. is 13.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of J2KBIO Co., Ltd. (420570)?
The operating margin of J2KBIO Co., Ltd. is 17.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at J2KBIO Co., Ltd. (420570)?
Revenue at J2KBIO Co., Ltd. is growing +53.1% versus a year earlier (3y avg +27.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at J2KBIO Co., Ltd. (420570)?
Earnings per share at J2KBIO Co., Ltd. are growing +565% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch J2KBIO Co., Ltd. in the live analysis
One click puts J2KBIO Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
